Selective Alpha-7 Nicotinic Agonists for Cognitive Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for neurological disorders such as Alzheimer's, Parkinson's, and nicotine addiction lack selective agonists for the alpha7 nicotinic acetylcholine receptor (α7 nAChR), leading to inadequate treatment efficacy and significant side effects due to non-specific nicotinic receptor stimulation.
Innovation Solution
Development of substituted 1,2,3-triazole compounds, such as 5-(1-(2-(Piperidin-1-yl)ethyl)-1H-1,2,3-triazol-4-yl)-1H-indole (IND1), with high affinity and selectivity for α7 nAChR, formulated in various pharmaceutical compositions for administration via different routes, including oral, parenteral, and topical methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If non-specific nicotinic receptor agonists are used, then treatment coverage is broad, but selectivity and side effect profile deteriorate
Solution Approach 1:
The patent applies local quality by designing agonists with specific molecular structures (containing a basic amine and a hydrophobic moiety at specific distances) that create selective binding to α7 nAChR. The compound structure is optimized so that the basic amine forms a salt bridge with Asp3.31 and the hydrophobic moiety interacts with specific residues in the binding pocket, achieving high selectivity for α7 over other nicotinic receptor subtypes.
2Reliability
If existing nicotinic receptor agonists are used, then cognitive function may be improved, but side effects increase due to lack of selectivity
Solution Approach 1:
The patent applies parameter changes by systematically varying the distance between the basic amine and hydrophobic moiety (3.7-3.8 Å optimal), modifying the pKa of the basic amine (8.0-10.0), and adjusting the hydrophobicity of the R2 group to optimize α7 selectivity. These parameter optimizations enable cognitive improvement through α7 activation while minimizing side effects from off-target receptor stimulation.
3Manufacturing precision
If substituted 1,2,3-triazole compounds are developed, then affinity and selectivity for α7 nAChR are improved, but synthesis complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the synthesis into modular steps: first synthesizing the substituted 1,2,3-triazole core compound, then separately preparing the indole or other hydrophobic moiety, and finally coupling them together. This modular approach allows optimization of each segment independently and simplifies the overall synthesis process while maintaining high affinity and selectivity.
Data Source
AI summary
In alternative embodiments, provided are selective agonists having a high affinity for the alpha7 nicotinic acetylcholine receptor (α7 nAChR), assays for selectivity of nicotinic receptor subtype and ligand-gated ion channel subtype based on receptor occupation and response, behavioral assessments for reversing cognitive impairment after scopolamine treatment, enhancing memory retention over time, pharmaceutical compositions and formulations and devices comprising them, and methods for making and using them, including characterizing and efficiently assaying them for receptor subtype selectivity. In alternative embodiments, provided are substituted anti 1,2,3-triazoles compounds with high affinity, and selective binding, for the alpha7 nicotine acetylcholine receptor (α7 nAChR), as exemplified by 5-(1-(2-(Piperidin-1-yl)ethyl)-1H-1,2,3-triazol-4-yl)-1H-indole (“IND1”), 5-((quinuclid-3-yl)-1H-1,2,3-triazol-4-yl)-1H-indole (“IND8”) and 3-(4-hydroxyphenyl-1,2,3-triazol-1-yl) quinuclidine (“QND8”). In alternative embodiments, provided are products of manufacture such as pumps, devices, syringes and the like comprising a compound, pharmaceutical composition or formulation as provided herein.